CHMP7 Gene: Potential Drug Target Or Biomarker (G91782)

Target Name: CHMP7

NCBI ID: G91782

CHMP7

CHMP7 Gene: Potential Drug Target Or Biomarker

CHMP7, also known as CHMP7 variant 1, is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The CHMP7 gene is a member of the heat shock protein (HSP) gene family, which are known for their ability to survive and function in high temperatures, such as those experienced by cells during the production of proteins in response to stress.

The CHMP7 gene has been shown to play a role in a variety of cellular processes, including the regulation of protein synthesis, DNA replication, and cell survival. It is also involved in the formation of stress-proteins, which are proteins that are produced in response to stress conditions, such as high temperatures or radiation.

One of the key features of the CHMP7 gene is its ability to undergo a process called polycombination, which involves the formation of multiple copies of a gene in response to stress. This process is thought to be involved in the regulation of cellular stress responses and may be a potential drug target or biomarker for stress-related diseases.

In addition to its role in stress responses, the CHMP7 gene has also been shown to be involved in the regulation of protein synthesis and cell survival. It is known to play a role in the regulation of the translation of genes into proteins, as well as in the regulation of cell cycle progression and apoptosis.

The CHMP7 gene is also thought to be involved in the development and progression of certain neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. Studies have shown that the CHMP7 gene is expressed in the brains of individuals with these disorders, and that it is involved in the development of neurodegeneration.

In addition to its potential role in neurodegenerative disorders, the CHMP7 gene is also being studied as a potential drug target or biomarker for cancer. Studies have shown that the CHMP7 gene is expressed in a variety of cancer types, including breast, ovarian, and prostate cancer. Additionally, research has suggested that the CHMP7 gene may be involved in the development and progression of certain types of cancer, such as melanoma and lung cancer.

Overall, the CHMP7 gene is a promising candidate for drug targeting or biomarker research due to its involvement in a variety of cellular processes, including stress responses, protein synthesis, cell survival, and the development and progression of certain neurodegenerative disorders. Further research is needed to fully understand the role of the CHMP7 gene in these processes and to determine its potential as a drug target or biomarker.

Protein Name: Charged Multivesicular Body Protein 7

Functions: ESCRT-III-like protein required to recruit the ESCRT-III complex to the nuclear envelope (NE) during late anaphase (PubMed:26040712). Together with SPAST, the ESCRT-III complex promotes NE sealing and mitotic spindle disassembly during late anaphase (PubMed:28242692, PubMed:26040712). Recruited to the reforming NE during anaphase by LEMD2 (PubMed:28242692). Plays a role in the endosomal sorting pathway (PubMed:16856878)

The "CHMP7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHMP7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets